Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.
Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.
Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.
Kura Oncology (Nasdaq: KURA) announced its participation in the JMP Securities Life Sciences Conference, with CEO Troy Wilson scheduled for a virtual presentation on June 17, 2021, at 3:00 p.m. ET. The live audio webcast will be accessible on Kura's website, with a replay available afterward. Kura focuses on precision medicines for cancer treatment, with promising candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancers, including acute myeloid leukemia and HRAS mutant head and neck cancer.
Kura Oncology (Nasdaq: KURA) announced the appointment of Carol Schafer to its board of directors, effective June 3, 2021. With over 25 years of experience in healthcare investment banking, including her recent role as Vice Chair of Equity Capital Markets at Wells Fargo Securities, Schafer is expected to contribute significantly to Kura’s strategic initiatives. She will succeed Robert Hoffman, who is stepping down from the board on August 3, 2021, after six years of service. Kura's pipeline includes promising cancer treatment candidates like KO-539 and Tipifarnib.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. CEO Troy Wilson will present in a fireside chat on May 20, 2021, at 10:20 a.m. PT. A live audio webcast will be available on the company's website, with a replay following the event. Kura's pipeline includes KO-539, a menin inhibitor in a Phase 1/2 trial, and Tipifarnib, a farnesyl transferase inhibitor with Breakthrough Therapy Designation, currently in a registration-directed study for head and neck cancer.
Kura Oncology reported its Q1 2021 financial results, highlighting the promising clinical activity and safety profile of its menin inhibitor KO-539. The KOMET-001 trial has been amended to include Phase 1b expansion cohorts for NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients. Kura maintains a solid financial position with $603.9 million in cash, expected to fund operations into 2024. The company also announced a publication of tipifarnib trial data in the Journal of Clinical Oncology and received Breakthrough Device Designation for an HRAS companion diagnostic.
Kura Oncology (KURA) will report its Q1 2021 financial results on May 6, 2021, after the U.S. markets close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed by dialing the provided numbers. Kura focuses on precision cancer treatments, with notable therapies in its pipeline, including KO-539 for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer, which has received Breakthrough Therapy Designation.
Kura Oncology reported significant results from the Phase 2 RUN-HN trial of tipifarnib for HRAS mutant head and neck squamous cell carcinoma (HNSCC). The objective response rate (ORR) was 55%, with a median progression-free survival (PFS) of 5.6 months, outperforming previous therapies which had a PFS of 3.6 months (p=0.0012). The median overall survival (OS) was recorded at 15.4 months. The safety profile was consistent with earlier data, supporting the advancement of the AIM-HN registration-directed trial. These findings underscore the potential of genomic testing in identifying suitable candidates for tipifarnib treatment.
Kura Oncology reported positive developments regarding its clinical pipeline and financial results for 2020. Preliminary data for KO-539 showed significant single-agent activity in relapsed AML patients, particularly those with NPM1 mutations. The FDA granted Breakthrough Therapy Designation to tipifarnib for treating recurrent HRAS mutant HNSCC. Financially, the company ended 2020 with $633.3 million in cash, ensuring operational funding into 2024. However, Kura also reported an increase in net losses, reaching $89.6 million for the year.
Kura Oncology (Nasdaq: KURA) announced that its drug tipifarnib has received Breakthrough Therapy Designation from the FDA for treating recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC). This designation is based on promising data from the RUN-HN Phase 2 trial, which indicated a 50% objective response rate and improved median overall survival of 15.4 months. HNSCC, with over 885,000 new cases annually, has a poor prognosis and limited treatment options. Tipifarnib also holds Fast Track designation, enhancing its development pathway.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that its CEO, Troy Wilson, will participate in four virtual investor conferences in February and March 2021. Key events include a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, a panel discussion at the Cowen 41st Annual Health Care Conference on March 3, and a presentation at the Barclays Virtual Global Healthcare Conference on March 10. Kura's drug candidates, including tipifarnib and KO-539, target specific cancer signaling pathways to enhance treatment outcomes.
Kura Oncology, Inc. (Nasdaq: KURA) announced it will report its fourth quarter and full year 2020 financial results on February 24, 2021, before U.S. markets open. Management will host a conference call at 8:00 a.m. ET to discuss these results and provide a corporate update. The company is focused on developing precision medicines for cancer treatment, with two key candidates: tipifarnib for HRAS mutant head and neck cancer, and KO-539 for acute myeloid leukemia, currently in clinical trials. For details, visit their website.
